{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"3.38","upperLimit":"8.31","value":"5.95"},{"groupId":"OG001","lowerLimit":"6.67","upperLimit":"20.27","value":"12.35"},{"groupId":"OG002","lowerLimit":"5.68","upperLimit":"11.93","value":"7.31"}]}],"title":"HGRF Survival"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"6.9","upperLimit":"21.5","value":"13.2"},{"groupId":"OG001","lowerLimit":"19.5","upperLimit":"46.6","value":"32.7"},{"groupId":"OG002","lowerLimit":"12.6","upperLimit":"26.4","value":"19.0"}]}],"title":"Probability of duration of HGRF survival for 57 months"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"10.1","upperLimit":"24.9","value":"16.7"},{"groupId":"OG001","lowerLimit":"19.5","upperLimit":"46.6","value":"32.7"},{"groupId":"OG002","lowerLimit":"15.2","upperLimit":"28.8","value":"21.6"}]}],"title":"Probability of duration of HGRF survival for 48 months"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"12.2","upperLimit":"27.6","value":"19.3"},{"groupId":"OG001","lowerLimit":"19.5","upperLimit":"46.6","value":"32.7"},{"groupId":"OG002","lowerLimit":"17.0","upperLimit":"30.8","value":"23.6"}]}],"title":"Probability of duration of HGRF survival for 36 months"}],"denoms":[{"counts":[{"groupId":"OG000","value":"103"},{"groupId":"OG001","value":"48"},{"groupId":"OG002","value":"151"}],"units":"Participants"}],"description":"HGRF survival was defined as the time from the first dose to the first recurrence of high-grade disease (including muscle-invasive disease progression and death due to any cause). Patients without high-grade disease recurrence were censored at the last disease assessment not showing high-grade disease recurrence.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients with Carcinoma in situ (CIS) with or without concomitant high-grade Ta or T1 papillary disease","id":"OG000","title":"Carcinoma in Situ"},{"description":"Patients with high-grade Ta or T1 papillary disease (without concomitant CIS)","id":"OG001","title":"Papillary Disease"},{"description":"All Patients","id":"OG002","title":"Total"}],"paramType":"MEDIAN","populationDescription":"Patients with no recurrence of high-grade disease","reportingStatus":"POSTED","timeFrame":"Up to 57 months","title":"Durability of High-grade-recurrence-free Survival in Patients With High-grade Ta or T1 Papillary Disease (With or Without Concomitant CIS)","type":"SECONDARY","unitOfMeasure":"Months"}